Financhill
Sell
16

RAFA Quote, Financials, Valuation and Earnings

Last price:
$0.0600
Seasonality move :
143.53%
Day range:
$0.0560 - $0.0560
52-week range:
$0.0330 - $0.1790
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
--
Avg. volume:
28.8K
1-year change:
12%
Market cap:
$4.7M
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    No consensus rating exists at this time due to lack of analyst coverage.
  • Price Target Downside
    No price target exists because of limited analyst coverage.
  • Price Target Upside
    Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

  • According to the consensus of 0 analysts, Rafarma Pharmaceuticals has -- downside to fair value with a price target of -- per share.

RAFA vs. S&P 500

  • Over the past 5 trading days, Rafarma Pharmaceuticals has underperformed the S&P 500 by -18.16% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Rafarma Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Rafarma Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rafarma Pharmaceuticals reported revenues of --.

Earnings Growth

  • Rafarma Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rafarma Pharmaceuticals reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2023-06-28 2024-06-28 2024-06-28
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2021-06-28 2022-06-28 2023-06-28 2024-06-28
Balance Sheet
Current Assets -- -- -- -- --
Total Assets -- -- -- -- --
Current Liabilities -- -- -- -- --
Total Liabilities -- -- -- -- --
Total Equity -- -- -- -- --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2023-06-28 2024-06-28 2024-06-28
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
RAFA
Sector
Market Cap
$4.7M
--
Price % of 52-Week High
31.29%
--
Dividend Yield
0%
--
Shareholder Yield
--
--
1-Year Price Total Return
12%
--
Beta (5-Year)
1.095
--
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.0597
200-day SMA
Sell
Level $0.0992
Bollinger Bands (100)
Sell
Level 0.0857 - 0.1457
Chaikin Money Flow
Sell
Level --
20-day SMA
Sell
Level $0.0721
Relative Strength Index (RSI14)
Sell
Level 33.9718
ADX Line
Neutral
Level
Williams %R
Buy
Level -95.7983
50-day SMA
Sell
Level $0.0895
MACD (12, 26)
Buy
Level 0.0045
25-day Aroon Oscillator
Sell
Level -80
On Balance Volume
Neutral
Level --

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Rafarma Pharmaceuticals Inc is engaged in pharmaceuticals and has several subsidiaries specializing in developing and producing medical equipment, as well as supplying equipment for hospitals and clinics from Germany, China, Slovakia, and others.

Stock Forecast FAQ

In the current month, RAFA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RAFA average analyst price target in the past 3 months is --.

  • Where Will Rafarma Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Rafarma Pharmaceuticals share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About Rafarma Pharmaceuticals?

    Analysts are divided on their view about Rafarma Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rafarma Pharmaceuticals is a Sell and believe this share price will rise from its current level to --.

  • What Is Rafarma Pharmaceuticals's Price Target?

    The price target for Rafarma Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is RAFA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Rafarma Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of RAFA?

    You can purchase shares of Rafarma Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rafarma Pharmaceuticals shares.

  • What Is The Rafarma Pharmaceuticals Share Price Today?

    Rafarma Pharmaceuticals was last trading at $0.0600 per share. This represents the most recent stock quote for Rafarma Pharmaceuticals. Yesterday, Rafarma Pharmaceuticals closed at $0.0560 per share.

  • How To Buy Rafarma Pharmaceuticals Stock Online?

    In order to purchase Rafarma Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is Planet Labs Stock Up Today?
Why Is Planet Labs Stock Up Today?

Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…

Is Coherent Stock Breaking Out?
Is Coherent Stock Breaking Out?

Coherent (NYSE: COHR) has spent the better part of two years…

What Is The Long-term Outlook for AMC Stock?
What Is The Long-term Outlook for AMC Stock?

Meme stock extraordinaire AMC Entertainment Holdings, Inc. (NYSE:AMC) has long…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
95
AVAV alert for Jun 27

AeroVironment [AVAV] is up 2.13% over the past day.

Buy
70
AEVA alert for Jun 27

Aeva Technologies [AEVA] is up 8.52% over the past day.

Buy
88
TSSI alert for Jun 27

TSS [TSSI] is down 2.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock